Baroldi Joseph

SEC source: 0000874015-25-000215 · edgardoc.xml · nonDerivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,926

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000215 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,926

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.59 to $59.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000215 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,726

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000118 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,926

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.37 to $28.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000118 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,511

Underlying: Common Stock · 10,837 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000118 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000055 · edgardoc.xml · nonDerivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 3,071

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-25-000055 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,017

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-25-000055 · edgardoc.xml · derivative · entry 9

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 8,324

Underlying: Common Stock · 2,460 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000055 · edgardoc.xml · derivative · entry 8

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 10,784

Underlying: Common Stock · 3,750 shares

Expires not disclosed

F8 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000055 · edgardoc.xml · derivative · entry 7

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,348

Underlying: Common Stock · 8,787 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000055 · edgardoc.xml · derivative · entry 6

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,135

Underlying: Common Stock · 33,000 shares

Expires not disclosed

F5 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000055 · edgardoc.xml · derivative · entry 5

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,290

Underlying: Common Stock · 22,000 shares

Expires not disclosed

F3 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F4 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-25-000055 · edgardoc.xml · nonDerivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 4,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-25-000055 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,418

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-25-000015 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2035-01-01

F2 · derivative.exercise_date: Grant on 01/02/2025 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-25-000015 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000139 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,631

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $41.65 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-24-000139 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,135

Underlying: Common Stock · 10,838 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000139 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-24-000072 · edgardoc.xml · nonDerivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 1,640

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-24-000072 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,799

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-24-000072 · edgardoc.xml · derivative · entry 6

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 7,034

Underlying: Common Stock · 1,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000072 · edgardoc.xml · derivative · entry 5

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,973

Underlying: Common Stock · 3,688 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000072 · edgardoc.xml · nonDerivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 2,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F4 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-24-000072 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,259

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 8,387

Underlying: Common Stock · 2,625 shares

Expires not disclosed

F6 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 5,762

Underlying: Common Stock · 1,800 shares

Expires not disclosed

F6 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,661

Underlying: Common Stock · 20,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000049 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,290

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000017 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 3,500

Underlying: Common Stock · 3,500 shares

Expires 2034-01-01

F2 · derivative.exercise_date: Grant on 01/02/2024 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000017 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Stock · 27,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-23-000206 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Spouse

Disclosed balance after: 2,400

Underlying: Common Stock · 2,400 shares

Expires 2034-09-30

F1 · derivative.exercise_date: Grant on 10/1/2023 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 10/1/2023. 25% of the shares subject to the option will vest and become exercisable on 10/1/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-23-000130 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,571

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.20 to $36.50953 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000130 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,261

Underlying: Common Stock · 10,838 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000130 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,451

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-23-000061 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Spouse

Disclosed balance after: 851

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.76975 to $39.79032 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000061 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Spouse

Disclosed balance after: 3,962

Underlying: Common Stock · 904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000061 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Spouse

Disclosed balance after: 1,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-23-000042 · edgardoc.xml · derivative · entry 3

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Spouse

Disclosed balance after: 4,866

Underlying: Common Stock · 1,800 shares

Expires not disclosed

F6 · security: Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000042 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,099

Underlying: Common Stock · 14,749 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000042 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,290

Underlying: Common Stock · 12,290 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-23-000010 · edgardoc.xml · derivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Spouse

Disclosed balance after: 2,400

Underlying: Common Stock · 2,400 shares

Expires 2033-01-02

F2 · derivative.exercise_date: Grant on 01/03/2023 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2023. 25% of the shares subject to the option will vest and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-23-000010 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,665

Underlying: Common Stock · 19,665 shares

Expires 2033-01-02

F1 · derivative.exercise_date: Grant on 01/03/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2023. 25% of the shares subject to the option will vest and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-22-000098 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,350

Underlying: Common Stock · 43,350 shares

Expires not disclosed

F1 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000070 · edgardoc.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,700

Underlying: Common Stock · 86,700 shares

Expires 2032-01-30

F1 · derivative.exercise_date: Grant on 01/31/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/31/2022. 25% of the shares subject to the option will vest and become exercisable on 01/31/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0001209191-21-007737 · doc4.xml · derivative · entry 1

Baroldi Joseph · CIK 0001813775 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2031-02-01

F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 1, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.